Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting may soothe aromatase inhibitor side effects

NCT ID NCT06172088

Symptom relief Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a 7-day supervised fast (max 350 calories per day) could reduce muscle and joint pain in 54 breast cancer patients taking aromatase inhibitors. The goal was to see if fasting is feasible and improves physical well-being and quality of life. Researchers also tested a new app to track symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
therapeutic fasting (7-day prolonged fast, max 350 kcal/day)
What this could lead to
If it works, this could offer a drug-free way to reduce muscle and joint pain for breast cancer patients on hormone therapy.
What could go wrong
This is a small, early exploratory study with only 54 participants, so results may not apply widely. Fasting can be hard to stick with and may not be safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Dec 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with curatively treated hormone receptor positive breast cancer who have been on aromatase inhibitors (AI) therapy for at least 3 months and have significant Pain (NRS\>4). * Informed consent. Exclusion Criteria: * Eating disorders. * Permanent medication other than endocrine therapy, which would constitute an absolute or relative contraindication to outpatient fasting, such as Marcumar, lithium, Antiepileptic drugs, etc. * Patients with diabetes mellitus type 1 or 2 * Uncontrolled cerebral seizure disorder. * Participation in another diet/fasting study. * Lack of willingness to store and share personal medical data within the framework of the protocol. * Insufficient knowledge of the German language.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer Fasting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer patients treated with aromatase inhibitors

Contacts and locations

Locations

  • Robert-Bosch-Krankenhaus

    Stuttgart, Baden Würtenberg, 70341, Germany

  • Würzburg University

    Würzburg, Bavaria, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.